Zacks: Brokerages Anticipate Alphatec Holdings, Inc. (NASDAQ:ATEC) to Post -$0.22 EPS

Equities research analysts forecast that Alphatec Holdings, Inc. (NASDAQ:ATEC) will announce ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Alphatec’s earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.15). Alphatec reported earnings per share of ($0.18) during the same quarter last year, which would suggest a negative year-over-year growth rate of 22.2%. The firm is scheduled to announce its next earnings results on Thursday, November 4th.

On average, analysts expect that Alphatec will report full year earnings of ($1.13) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to ($1.06). For the next year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.92) to ($0.06). Zacks’ earnings per share averages are an average based on a survey of analysts that follow Alphatec.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Monday, August 2nd. The medical technology company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.20). The company had revenue of $62.25 million during the quarter, compared to the consensus estimate of $51.20 million. Alphatec had a negative return on equity of 86.64% and a negative net margin of 54.09%.

A number of research analysts recently issued reports on the stock. Needham & Company LLC assumed coverage on shares of Alphatec in a report on Wednesday, August 25th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research lowered shares of Alphatec from a “hold” rating to a “sell” rating in a report on Tuesday, July 13th. Piper Sandler raised their price objective on shares of Alphatec from $19.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, August 4th. Canaccord Genuity raised their price objective on shares of Alphatec from $21.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 4th. Finally, Cowen assumed coverage on shares of Alphatec in a report on Wednesday, August 4th. They issued an “outperform” rating and a $22.50 price objective for the company. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $19.31.

In other news, SVP Scott Lish sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 3rd. The shares were sold at an average price of $14.24, for a total transaction of $142,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Jennifer N. Pritzker acquired 2,000 shares of Alphatec stock in a transaction dated Friday, August 27th. The shares were bought at an average cost of $13.26 per share, with a total value of $26,520.00. Following the transaction, the insider now owns 38,200 shares in the company, valued at $506,532. The disclosure for this purchase can be found here. Insiders have acquired a total of 5,631 shares of company stock valued at $75,312 in the last three months. Insiders own 34.38% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its position in shares of Alphatec by 17.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,397 shares of the medical technology company’s stock worth $83,000 after buying an additional 785 shares during the period. Altshuler Shaham Ltd grew its position in shares of Alphatec by 103.4% during the 1st quarter. Altshuler Shaham Ltd now owns 6,223 shares of the medical technology company’s stock worth $98,000 after buying an additional 3,164 shares during the period. O Shaughnessy Asset Management LLC acquired a new stake in shares of Alphatec during the 1st quarter worth approximately $118,000. Pinz Capital Management LP acquired a new stake in shares of Alphatec during the 1st quarter worth approximately $129,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Alphatec during the 1st quarter worth approximately $158,000. 44.75% of the stock is owned by institutional investors.

ATEC stock opened at $14.30 on Wednesday. The stock has a market capitalization of $1.43 billion, a P/E ratio of -11.53 and a beta of 1.58. The company has a current ratio of 1.92, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. Alphatec has a 12 month low of $5.88 and a 12 month high of $19.36. The firm has a 50-day moving average price of $13.97 and a 200-day moving average price of $15.09.

Alphatec Company Profile

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.

Read More: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Alphatec (ATEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.